Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial
Authors:
- Eva-Maria PöllabauerEPEva-Maria Pöllabauer
- Gerald AichingerGAGerald Aichinger
- Daniel PortsmouthDPDaniel Portsmouth
- Alexandra Löw-BaselliALAlexandra Löw-Baselli
- Sandor FritschSFSandor Fritsch
- Ian LiveyILIan Livey
- Brian A CroweBCBrian A Crowe
- Michael SchwendingerMSMichael Schwendinger
- Peter BrühlPBPeter Brühl
- Andreas PilzAPAndreas Pilz
- Thomas DvorakTDThomas Dvorak
- 1 August 2013
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 13 (8) , 680-689
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Differentiation of Reinfection from Relapse in Recurrent Lyme DiseaseNew England Journal of Medicine, 2012
- A New Approach to a Lyme Disease VaccineClinical Infectious Diseases, 2011
- Vaccines against Lyme Disease: What Happened and What Lessons Can We Learn?Clinical Infectious Diseases, 2011
- Relationship between Immunity to Borrelia burgdorferi Outer-surface Protein A (OspA) and Lyme ArthritisClinical Infectious Diseases, 2011
- Lyme borreliosis: Clinical case definitions for diagnosis and management in EuropeClinical Microbiology and Infection, 2011
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Outer Surface Protein A Protects Lyme Disease Spirochetes from Acquired Host Immunity in the Tick VectorInfection and Immunity, 2008
- Structural identification of a key protective B-cell epitope in lyme disease antigen OspAJournal of Molecular Biology, 2000
- Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 monthsClinical Therapeutics, 2000
- Alternative Vaccination Schedules (0, 1, and 6 Months Versus 0, 1, and 12 Months) for a Recombinant OspA Lyme Disease VaccineClinical Infectious Diseases, 1999